CP and neoplasm: The liver and kidneys seem to be especially affected, as shown by Tian et al. [128], who analyzed PLGA-PEG NPs delivering PTX and fatty acid-modified CP prodrug (CPP) to lung cancer cell lines [155], founding miscellaneous NPs biodistributed to the tumor target as well as the liver and the spleen.